GlassScriptPhysician profile
Michael James Dasilva
NPI 1992237903
$2,547.94
in general payments reported to CMS, 2019-2025
12 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2021: $98.85 · 2022: $1,188 · 2024: $264 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $932.20 | 2022 | |
| Alcon Vision LLC | $690.31 | 2019-2025 | Rocklatan, Tryptyr, Clareon |
| Abbvie INC. | $234.28 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $189.62 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| New World Medical,INC. | $161.44 | 2022 | |
| Biotissue Holdings INC. | $128.87 | 2022-2025 | |
| Astellas Pharma US INC | $70.80 | 2024-2025 | Izervay |
| Oyster Point Pharma, INC. | $53.24 | 2024 | Tyrvaya |
| Glaukos Corporation | $33.34 | 2024-2025 | Idosetr, Idose |
| Sun Pharmaceutical Industries INC. | $19.85 | 2025 | |
| Topcon Healthcare, INC. | $18.45 | 2025 | |
| Rxsight INC | $15.54 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$64,220.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dasilva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.